논문 검색
-
Lenvatinib potentiates the antitumor efficacy of combined radiotherapy and PD-L1 blockade in lung adenocarcinoma.
[BACKGROUND] The potential of Lenvatinib to synergize with combined radiotherapy and immunotherapy in LUAD remains incompletely characterized. [METHODS] We investigated Lenvatinib's effects on radiation-induced PD-L1 in LUAD cells and VEGF…
FULLTEXT: paradigm shift versus -
TNF-α deficiency underlies NK cell dysfunction in colorectal cancer.
Natural killer (NK) cells are central to innate antitumor immunity, yet their function is systemically compromised in colorectal cancer (CRC). We show that CRC patients exhibit early and pronounced alterations in peripheral blood NK cells, …
FULLTEXT: paradigm shift versus -
The distinct roles of and in proximal- and late-onset colorectal cancer.
Despite the emerging role of the gut microbiome in colorectal cancer (CRC), its significance in early-onset CRC (EOCRC, …
FULLTEXT: paradigm shift versus -
Temporal trends in second primary malignancies among long-term survivors of multiple myeloma across treatment eras: a population-based analysis of the SEER database.
[OBJECTIVE] To evaluate temporal trends in second primary malignancy (SPM) risk among long-term multiple myeloma (MM) survivors across treatment eras. [METHODS] This retrospective cohort study utilized the SEER 17 registries database (1975…
FULLTEXT: paradigm shift versus -
The interplay between autophagy, p16, and senescence in tumor cells: a systematic review.
Autophagy and cellular senescence are fundamental determinants of tumor cell fate. p16 has emerged as a key regulator at the intersection of these processes, yet its mechanistic role in the autophagy - senescence axis remains incompletely d…
FULLTEXT: paradigm shift versus -
Adding anti-PD-1 antibody to definitive chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: higher intensity does not equate to better outcomes.
[BACKGROUND AND PURPOSE] The benefit of adding anti-PD-1 antibodies to definitive chemoradiotherapy (dCRT) in elderly patients with esophageal squamous cell carcinoma (ESCC) remains uncertain. This study evaluated its efficacy and safety ve…
FULLTEXT: paradigm shift versus -
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.
[AIMS] In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-…
FULLTEXT: paradigm shift versus -
Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the United States.
[AIMS] Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma (CIS) is aggressive and treatment options are suboptimal. TAR-200, a novel intravesical drug-releasing system, receiv…
FULLTEXT: paradigm shift versus -
A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
[BACKGROUND AND AIM] Bruton tyrosine kinase inhibitors (BTKis) are the standard of care for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib and acalabrutinib are two commo…
FULLTEXT: paradigm shift versus -
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.
[BACKGROUND] Bruton tyrosine kinase inhibitors (BTKis) are therapeutic agents for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Previous indirect treatment comparisons are limited in simultaneously comparing multiple intervent…
FULLTEXT: paradigm shift versus -
A Randomized Trial Evaluating Intraoperative Ischemic Preconditioning of Parathyroid Glands During Total Thyroidectomy: A Signal for Earlier Parathyroid Function Recovery.
[BACKGROUND] Ischemic preconditioning of parathyroid glands (IPCP) is biologically plausible but clinical evidence is limited. In this single-center randomized trial (ChiCTR2000039788), we compared IPCP versus control during total thyroidec…
FULLTEXT: paradigm shift versus -
Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer.
Docetaxel (DTX) resistance is the main cause of treatment failure in castration-resistant prostate cancer (CRPC). Pyrroline-5-carboxylic acid reductase 1 (PYCR1) is an enzyme involved in proline metabolism. It is highly expressed in various…
FULLTEXT: paradigm shift versus -
Impact of Adjuvant Chemotherapy on Survival of the Patients with pT1N + M0 Gastric Cancer: A Retrospective Cohort Study.
[BACKGROUND] The advantages of postoperative adjuvant chemotherapy (ACT) for gastric cancer patients with pT1N + M0 staging have been a subject of debate. This study aims to assess whether ACT can enhance the overall survival (OS) of postop…
FULLTEXT: paradigm shift versus -
Ginkgolic acid targets HSPA8 to trigger ferroptosis in hepatocellular carcinoma chaperone-mediated autophagy-dependent GPX4 degradation.
[CONTEXT] Ginkgolic acid (GAC), one of the major active constituents of extract, has been reported as a potential anticancer agent. [OBJECTIVE] To investigate the effect of GAC on the viability of human hepatocellular carcinoma (HCC) cell…
FULLTEXT: paradigm shift versus -
Causal Caution Before Declaring Superiority of Liver Resection Versus Radiofrequency Ablation for Very Early-Stage Hepatocellular Carcinoma.
FULLTEXT: paradigm shift versus
-
Model-based evaluation of colorectal cancer screening effectiveness: three rounds of multitarget stool DNA testing versus one colonoscopy.
[BACKGROUND] Several colorectal cancer (CRC) screening modalities are guideline-recommended in the United States but differ in screening interval and real-world adherence. Accordingly, single-round test performance may not reflect cumulativ…
FULLTEXT: paradigm shift versus -
DA-LUNGNET: a multi-stage deep framework with adaptive attention for early detection of subcentimeter pulmonary nodules.
Early and reliable detection of subcentimeter pulmonary nodules remains a major bottleneck in low-dose CT-based lung cancer screening due to high miss rates, vascular-adhesion-induced false positives, and insufficient multi-scale feature fu…
FULLTEXT: paradigm shift versus -
Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting.
[BACKGROUND] The lung is a uniquely innervated barrier organ with dynamic neuroimmune interactions that critically regulate respiratory homeostasis. Despite the well-characterized gut-brain axis, pulmonary neuroimmune crosstalk remains an u…
FULLTEXT: paradigm shift versus -
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.
[AIM] To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs). [METHODS] A survey of 105 clinical experts acro…
FULLTEXT: paradigm shift versus -
A Retrospective Comparative Study on the Omission Versus Placement of Chest Drain Following Thoracoscopic Sublobar Resection.
[PURPOSE] This study aims to investigate the clinical applicability of omitting chest drainage tube following thoracoscopic sublobar resection. [METHODS] We gathered data from 1,054 patients who met the inclusion criteria and underwent tho…
FULLTEXT: paradigm shift versus